ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

Frontiers In Medicine

by Shaoqing Yin, Jiaye Li, Wei Zhang, Rui Ding, Yan Li, Kai Wang, Wenjian Jiang, Yi-Da Tang, Zhengjun Yi, Yaohua Zhang, Meng Li
June 17, 2026

Frontiers In Oncology

Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study

by Yu He, Shun Wang, Yingchun Li, Xinyang Li, Jingkai Yi, Dan Wang, Kailin Qi, Yongjiang Li, Xiao Jiang, Yutang Yao, Ping Wu, Meng Zhao, Hao Lu, Taipeng Shen, Zhuzhong Cheng, Ying Kou
June 4, 2026

The Medicine Maker

This Week’s CGT News: Promising Data for In Vivo CAR T

Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts

June 8, 2026
6 min

Frontiers In Pediatrics

Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child

by Hongyu Huang, Jiao Chen, Lei Ye, Dan Yu
June 17, 2026

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

Original Source(s)

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

Related Content

Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study

This Week’s CGT News: Promising Data for In Vivo CAR T

Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child